Tokyo Tape
Sign in
← Taiko Pharmaceutical

Half-year report · Q2

4574.TEDINET S100U6M9
Period2024-01-01 → 2024-06-30
Filed2024-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥2.9bn2024-01-01 → 2024-06-30Cons.Net sales
Revenue¥6.1bn2023-01-01 → 2023-12-31Cons.Net sales (5-year summary)
Revenue¥2.5bn2023-01-01 → 2023-06-30Cons.Net sales
Operating income¥482m2024-01-01 → 2024-06-30Cons.Operating income
Operating income−¥396m2023-01-01 → 2023-06-30Cons.Operating income
Ordinary income¥528m2024-01-01 → 2024-06-30Cons.Ordinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥510m2023-01-01 → 2023-06-30Cons.Ordinary income
Profit before tax¥724m2024-01-01 → 2024-06-30Cons.Income before income taxes
Profit before tax−¥492m2023-01-01 → 2023-06-30Cons.Income before income taxes
Net income (owners)¥764m2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥3.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥514m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income¥764m2024-01-01 → 2024-06-30Cons.Profit loss
Net income−¥514m2023-01-01 → 2023-06-30Cons.Profit loss
Total assets¥13.4bnat 2024-06-30Cons.Assets
Total assets¥13.2bnat 2023-12-31Cons.Assets
Total assets¥15.6bnat 2023-06-30Cons.Total assets (5-year summary)
Total liabilities¥5.3bnat 2024-06-30Cons.Liabilities
Total liabilities¥6.5bnat 2023-12-31Cons.Liabilities
Net assets / equity¥8.1bnat 2024-06-30Cons.Net assets
Net assets / equity¥6.7bnat 2023-12-31Cons.Net assets
Net assets / equity¥9.2bnat 2023-06-30Cons.Net assets (5-year summary)
Cash and deposits¥5.2bnat 2024-06-30Cons.Cash and deposits
Cash and deposits¥5.5bnat 2023-12-31Cons.Cash and deposits
Cash & equivalents¥4.9bnat 2024-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.2bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.5bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.8bnat 2022-12-31dCons.Cash and cash equivalents
Operating cash flow¥256m2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥307m2023-01-01 → 2023-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥126m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥135m2024-01-01 → 2024-06-30Cons.Net cash provided by used in investment activities
Investing cash flow¥1.2bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥707m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥562m2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥1.5bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥827m2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥15.242024-01-01 → 2024-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-76.252023-01-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-11.362023-01-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio60.3%at 2024-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio51.0%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2023-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Otherother segmentsrevenue2024-01-01 → 2024-06-30¥2m
Otherother segmentsrevenue external2024-01-01 → 2024-06-30¥2m
Otherother segmentssegment profit2024-01-01 → 2024-06-30−¥6m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥401m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥203m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥203m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥195m
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥2.7bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥2.7bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-06-30¥1.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-06-30¥2.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-06-30¥2.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-06-30¥884m
Otherother segmentsrevenue2023-01-01 → 2023-06-30¥2m
Otherother segmentsrevenue external2023-01-01 → 2023-06-30¥2m
Otherother segmentssegment profit2023-01-01 → 2023-06-30−¥11m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥492m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥370m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥370m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥407m
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥514m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-06-30¥2.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-06-30¥2.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-06-30¥95m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 518
ItemContextValueUnit
Provision for loss on subleases nclPrior1YearInstant28000000JPY
Provision for loss on subleases nclCurrentQuarterInstant21000000JPY
Net defined benefit liabilityPrior1YearInstant624000000JPY
Net defined benefit liabilityCurrentQuarterInstant620000000JPY
Asset retirement obligations nclPrior1YearInstant20000000JPY
Asset retirement obligations nclCurrentQuarterInstant20000000JPY
Other nclPrior1YearInstant210000000JPY
Other nclCurrentQuarterInstant333000000JPY
Noncurrent liabilitiesPrior1YearInstant3433000000JPY
Noncurrent liabilitiesCurrentQuarterInstant2871000000JPY
LiabilitiesPrior1YearInstant6480000000JPY
LiabilitiesCurrentQuarterInstant5308000000JPY
Capital stockPrior1YearInstant2267000000JPY
Capital stockCurrentQuarterInstant10000000JPY
Capital surplusPrior1YearInstant2689000000JPY
Capital surplusCurrentQuarterInstant4997000000JPY
Retained earningsPrior1YearInstant1628000000JPY
Retained earningsCurrentQuarterInstant2393000000JPY
Treasury stockPrior1YearInstant-300000000JPY
Treasury stockCurrentQuarterInstant-273000000JPY
Shareholders equityPrior1YearInstant6284000000JPY
Shareholders equityCurrentQuarterInstant7126000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant91000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant469000000JPY
Foreign currency translation adjustmentPrior1YearInstant363000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant477000000JPY
Valuation and translation adjustmentsPrior1YearInstant454000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant947000000JPY
Subscription rights to sharesPrior1YearInstant0JPY
Subscription rights to sharesCurrentQuarterInstant－JPY
Net assetsPrior1YearInstant6739000000JPY
Net assetsCurrentQuarterInstant8074000000JPY
Liabilities and net assetsPrior1YearInstant13220000000JPY
Liabilities and net assetsCurrentQuarterInstant13383000000JPY
Net salesPrior1YTDDuration2488000000JPY
Net salesCurrentYTDDuration2860000000JPY
Cost of salesPrior1YTDDuration1437000000JPY
Cost of salesCurrentYTDDuration1181000000JPY
Gross profitPrior1YTDDuration1050000000JPY
Gross profitCurrentYTDDuration1678000000JPY
Selling general and administrative expensesPrior1YTDDuration1447000000JPY
Selling general and administrative expensesCurrentYTDDuration1196000000JPY
Operating incomePrior1YTDDuration-396000000JPY
Operating incomeCurrentYTDDuration482000000JPY
Interest income noiPrior1YTDDuration9000000JPY
Interest income noiCurrentYTDDuration15000000JPY
Foreign exchange gains noiPrior1YTDDuration28000000JPY
Foreign exchange gains noiCurrentYTDDuration38000000JPY
Restoration contribution income noiPrior1YTDDuration9000000JPY
Restoration contribution income noiCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass